Search Results - "Hickerson, Annelies T"

Correlation of tumor microenvironment from biopsy and resection specimens in untreated colorectal cancer patients: a surprising lack of agreement by Kemp Bohan, Phillip M., Chick, Robert C., Hickerson, Annelies T., Messersmith, Lynn M., Williams, Grant M., Cindass, Jessica L., Lombardo, Jamie, Collins, Ryan, Brady, Robert O., Hale, Diane F., Peoples, George E., Vreeland, Timothy J., Clifton, Guy T.

“…Background Colorectal cancer (CRC) tumor microenvironment (TME) characteristics, such as tumor infiltrating lymphocyte (TIL) densities and PD-L1 status, are…”
Get full text

Multi‐institutional, prospective, randomized, double‐blind, placebo‐controlled phase IIb trial of the tumor lysate, particle‐loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high‐risk melanoma patients: A subgroup analysis by Chick, Robert C., Faries, Mark B., Hale, Diane F., Kemp Bohan, Phillip M, Hickerson, Annelies T., Vreeland, Timothy J., Myers, John W., Cindass, Jessica L., Brown, Tommy A., Hyngstrom, John, Berger, Adam C., Jakub, James W., Sussman, Jeffrey J., Shaheen, Montaser, Clifton, Guy T., Park, Hyohyun, Sloan, Amanda J., Wagner, Thomas, Peoples, George E.

“…Background Checkpoint inhibitors (CPI) in combination with cell‐based vaccines may produce synergistic antitumor immunity. The primary analysis of the…”
Get full text

Immunologic and dose dependent effects of rapamycin and its evolving role in chemoprevention by O'Shea, Anne E., Valdera, Franklin A., Ensley, Daniel, Smolinsky, Todd R., Cindass, Jessica L., Kemp Bohan, Phillip M., Hickerson, Annelies T., Carpenter, Elizabeth L., McCarthy, Patrick M., Adams, Alexandra M., Vreeland, Timothy J., Clifton, Guy T., Peoples, George E.

“…Rapamycin inhibits the mechanistic (formally mammalian) target of rapamycin (mTOR), an evolutionarily conserved intracellular kinase that influences activation…”
Get full text

A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary Analysis by Vreeland, Timothy J., Clifton, Guy T., Hale, Diane F., Chick, Robert C., Hickerson, Annelies T., Cindass, Jessica L., Adams, Alexandra M., Bohan, Phillip M. Kemp, Andtbacka, Robert H. I., Berger, Adam C., Jakub, James W., Sussman, Jeffrey J., Terando, Alicia M., Wagner, Thomas, Peoples, George E., Faries, Mark B.

“…Background Melanoma therapy has changed dramatically over the last decade with improvements in immunotherapy, yet many patients do not respond to current…”
Get full text

Chemoprevention in familial adenomatous polyposis: past, present and future by Kemp Bohan, Phillip M., Mankaney, Gautam, Vreeland, Timothy J., Chick, Robert C., Hale, Diane F., Cindass, Jessica L., Hickerson, Annelies T., Ensley, Daniel C., Sohn, Vance, Clifton, G. Travis, Peoples, George E., Burke, Carol A.

“…Familial adenomatous polyposis (FAP) is a hereditary colorectal cancer syndrome characterized by colorectal adenomas and a near 100% lifetime risk of…”
Get full text

Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer by Chick, R. Connor, Clifton, G. Travis, Hale, Diane F., Vreeland, Timothy J., Hickerson, Annelies T., Kemp Bohan, Phillip M., McCarthy, Patrick M., Litton, Jennifer K., Alatrash, Gheath, Murthy, Rashmi K., Qiao, Na, Philips, Anne, Lukas, Jason, Holmes, Jarrod P., Mittendorf, Elizabeth A., Peoples, George E.

“…HER2-targeted therapy has not benefited patients with low levels of HER2 expression; however, combination therapy may be effective. Primary analysis of a phase…”
Get full text

Divergent clinical outcomes in a phase 2B trial of the TLPLDC vaccine in preventing melanoma recurrence and the impact of dendritic cell collection methodology: a randomized clinical trial by Adams, Alexandra M., Carpenter, Elizabeth L., Clifton, Guy T., Vreeland, Timothy J., Chick, Robert C., O’Shea, Anne E., McCarthy, Patrick M., Kemp Bohan, Phillip M., Hickerson, Annelies T., Valdera, Franklin A., Tiwari, Ankur, Hale, Diane F., Hyngstrom, John R., Berger, Adam C., Jakub, James W., Sussman, Jeffrey J., Shaheen, Montaser F., Yu, Xianzhong, Wagner, Thomas E., Faries, Mark B., Peoples, George E.

“…Background A randomized, double-blind, placebo-controlled phase 2b trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine was conducted in…”
Get full text

Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer by Clifton, G Travis, Hale, Diane, Vreeland, Timothy J, Hickerson, Annelies T, Litton, Jennifer K, Alatrash, Gheath, Murthy, Rashmi K, Qiao, Na, Philips, Anne V, Lukas, Jason J, Holmes, Jarrod P, Peoples, George E, Mittendorf, Elizabeth A

“…Preclinical data provide evidence for synergism between HER2-targeted peptide vaccines and trastuzumab. The efficacy of this combination was evaluated in…”
Get full text

Phase I Trial of Encapsulated Rapamycin in Patients with Prostate Cancer Under Active Surveillance to Prevent Progression by Kemp Bohan, Phillip M, Chick, Robert C, O'Shea, Anne E, Vreeland, Timothy J, Hickerson, Annelies T, Cindass, Jessica L, Ensley, Daniel C, Hale, Diane, Clifton, Guy T, Sohn, Vance Y, Thompson, Jr, Ian M, Peoples, George E, Liss, Michael A

“…No approved medical therapies prevent progression of low-grade prostate cancer. Rapamycin inhibits cell proliferation and augments immune responses, producing…”
Get full text

Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma by Adams, Alexandra M., Chick, Robert C., Vreeland, Timothy J., Clifton, Guy T., Hale, Diane F., McCarthy, Patrick M., O’Shea, Anne E., Bohan, Phillip M. Kemp, Hickerson, Annelies T., Park, Hyohyun, Sloan, Amanda JoEllen, Hyngstrom, John, Berger, Adam C., Jakub, James W., Sussman, Jeffrey J., Shaheen, Montaser, Wagner, Thomas, Faries, Mark B., Peoples, George E.

“…Immunotherapy has revolutionized the treatment of melanoma, yet survival remains poor for patients with metastatic disease. The autologous tumor lysate,…”
Get full text

Tumor lysate particle only vaccine (TLPO) vs. Tumor lysate particle-loaded, dendritic cell vaccine (TLPLDC) to prevent recurrence in resected stage III/IV melanoma patients: Results of a phase I/IIa trial by Van Decar, Spencer G., Carpenter, Elizabeth L., Adams, Alexandra M., Chick, Robert C., Clifton, Guy T., Stojadinovic, Alex, Vreeland, Timothy J., Valdera, Franklin A., Tiwari, Ankur, O'Shea, Anne E., McCarthy, Patrick M., Hale, Diane F., Bohan, Phillip M Kemp, Hickerson, Annelies T., Cindass, Jessica L., Hyngstrom, John, Berger, Adam C., Jakub, James W., Sussman, Jeffrey J., Shaheen, Montaser, Yu, Xianzhong, Wagner, Thomas, Faries, Mark B., Peoples, George E.

“…•Promoting a targeted host immune response via autologous tumor neoantigen vaccination is an evolving field.•Adjuvant autologous tumor vaccines (TLPO and…”
Get full text

Abstract 6537: Impact of disease-free interval on recurrence in high-risk melanoma patients in a phase IIb trial of the tumor lysate particle loaded dendritic cell (TLPLDC) vaccine by Chick, Robert Connor, Bohan, Phillip M. Kemp, Vreeland, Timothy J., Hickerson, Annelies T., Cindass, Jessica L., Hale, Diane F., Clifton, Guy Travis, Peoples, George E.

“…Abstract Background: Immunotherapy has become a mainstay of adjuvant treatment of advanced melanoma, but recurrence rates remain high. TLPLDC is a personalized…”
Get full text

Initial Safety and Production Efficacy of a Autologous Tumor Lysate Loaded Yeast Cell Wall Particle Vaccine by Hickerson, Annelies T., Brown, Tommy A., Peace, Kaitlin M., Cindass, Jessica L., Vreeland, Timothy J., Hale, Diane, Clifton, Guy T., Yu, Xianzhong, Peoples, George E.

Get full text

Results of a randomized phase IIb trial of nelipepimut-S + trastuzumab vs trastuzumab to prevent recurrences in high-risk HER2 low-expressing breast cancer patients by Clifton, G. Travis, Hale, Diane F., Vreeland, Timothy J., Hickerson, Annelies T., Litton, Jennifer K., Alatrash, Gheath, Murthy, Rashmi K., Qiao, Na, Philips, Anne, Lukas, Jason, Holmes, Jarrod P., Peoples, George E., Mittendorf, Elizabeth A.

Get full text

Abstract CT208: Prior vaccination with the autologous Tumor Lysate Particle Loaded Dendritic Cell (TLPLDC) Vaccine may impact clinical outcomes in melanoma patients treated with systemic therapies and re-vaccination by Hickerson, Annelies T., Clifton, Guy T., Brown, Tommy A., Cindass, Jessica L., Myers, John W., Vreeland, Timothy J., Hale, Diane F., Peace, Kaitlin M., Jackson, Doreen O., Herbert, Garth, Yu, Xianzhong, Wagner, Thomas E., Peoples, George E.

“…Abstract Background: Melanoma is an immunogenic cancer, yet only 50-60% of tumors respond to current immunotherapy. The autologous tumor lysate, particle…”
Get full text

Abstract 6536: Safety and efficacy of autologous tumor lysate particle loaded dendritic cell (TLPLDC) vaccination in combination with systemic therapies in patients with metastatic melanoma by Chick, Robert Connor, Hickerson, Annelies T., Clifton, Guy Travis, Bohan, Phillip M. Kemp, Brown, Tommy A., Cindass, Jessica L., Myers, John W., Vreeland, Timothy J., Jackson, Doreen O., Hale, Diane F., Peace, Kaitlin M., Herbert, Garth S., Yu, Xianzhong, Wagner, Thomas, Peoples, George E.

“…Abstract Background: The treatment of melanoma has changed drastically with the advent of immunotherapy, particularly checkpoint inhibition (CPI)…”
Get full text

Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma by Adams, Alexandra M., Chick, Robert C., Vreeland, Timothy J., Clifton, Guy T., Hale, Diane F., McCarthy, Patrick M., O’Shea, Anne E., Bohan, Phillip M Kemp, Hickerson, Annelies T., Park, Hyohyun, Sloan, Amanda JoEllen, Hyngstrom, John, Berger, Adam C., Jakub, James W., Sussman, Jeffrey J., Shaheen, Montaser, Wagner, Thomas, Faries, Mark B., Peoples, George E.

“…Immunotherapy has revolutionized the treatment of melanoma, yet survival remains poor for patients with metastatic disease. The autologous tumor lysate,…”
Get full text